314 results about "Tumor specific" patented technology

Provided herein are systems, compositions, and methods for generating immunogenic peptides or epitopes from tumor associated antigens (e.g., in vivo or ex vivo). Polynucleotides (e.g., genes) encoding the tumor associated antigens may be edited at selected target sites by nucleobase editors comprising a catalytically-inactive Cas9 and a cytosine deaminase, leading to the expression of heteroclitic or cryptic peptides that are more immunogenic than the native peptide derived from the tumor associated antigens. The heteroclitic or cryptic peptide elicit strong tumor-specific immune response (e.g., T-cell response or B-cell response), which inhibits tumor growth and metastasis.

Provided is a recombinant human serum albumin-collagen binding domain (CBD) fusion protein for tumor-specific targeting matrix and its use in specific targeted treatment of a solid tumor. HSA and the CBD generate gene fusion in the form of different molecular structures, and can be expressed in a constructed recombinant engineered host. A pharmaceutical recombinant fusion protein is obtained through large-scale fermentation. The recombinant fusion protein shows tumor-specific targeting of solid tumors and can be used as a starting material of a broad-spectrum matrix carrier. The recombinant fusion protein is coupled with any tumor treatment drug, small-molecule compound, or cytotoxic protein to form an innovative pharmaceutical composition. The pharmaceutical composition of the recombinant fusion protein is also long-acting, can prolong a half-life of the conjugate drug in vivo, and has a significantly better clinical curative efficacy on anti-tumor than that of a monomer drug.

The invention provides a tumor cell vaccine as well as a preparation method and application thereof. The preparation method comprises the following steps: acquiring and culturing tumor cells; enabling the cell membrane of the tumor cell to express a targeting antibody by utilizing a gene vector infection or gene editing technology, and enabling the targeting antibody to be used for enabling the tumor vaccine to be combined with the dendritic cell; performing overexpression of tumor specific protein on the cell membrane surface of the tumor cell by using a gene vector infection or gene editing technology; a nucleic acid substance of a target protein is wrapped by lipid nanoparticles to form a vaccine framework, and the nucleic acid substance can enable target cells to express directional chemotactic molecules; wherein the directed chemotactic molecule is used for transferring the dendritic cells to lymph nodes; the target vaccine is obtained by wrapping the vaccine framework with the cell membranes of the tumor cells, lymph node homing of the dendritic cells can be promoted, and the antigen presentation efficiency is increased and the immune effect is enhanced through tumor specific protein carried by the target vaccine and assisted by an immunologic adjuvant.

The invention relates to the technical field of nano-drug presentation systems, in particular to a TCR (T cell receptor) nano-vesicle antibody with both T cell redirection and immunosuppression reversal as well as a preparation method and application of the TCR nano-vesicle antibody. The TCR nano-vesicle antibody comprises a vesicle formed by a liposome and a cell membrane; tCR protein, a PD-1 antibody and a CD3 antibody are loaded on the vesicles. The nano vesicle antibody has the functions of T cell redirection and immunosuppression reversion; the difficulty of low stability of the soluble TCR is overcome; the polypeptide can be rapidly enriched in tumor tissues through tumor specificity TCR, and CD8 + T cells infiltrated by tumors are directly activated through an anti-CD3 antibody; depletion of T cells can be reversed through the PD-1 antibody on the surface, and the effector function of tumor infiltration CD8 + T cells is improved. The technical scheme can solve the technical problems that the TCR stability is not ideal and the immunosuppression state of the tumor microenvironment is difficult to overcome, and has ideal application and popularization prospects.

The invention discloses an anti-tumor drug delivery system based on click chemistry and a hollow covalent organic framework material as well as a preparation method and application of the anti-tumor drug delivery system, and belongs to the technical field of novel biomedical materials. The anti-tumor drug delivery system based on the click chemistry and the hollow covalent organic framework material comprises a bowl-shaped hollow covalent organic framework material carrier, and a click chemistry prodrug 1 and a click chemistry prodrug 2 which are loaded in the bowl-shaped hollow covalent organic framework material carrier, the click chemistry prodrug 1 is a compound containing an aldehyde group, and the click chemistry prodrug 2 is a compound containing an amino group. By combining the high-specificity reaction of click chemistry with the excellent drug loading performance of HCOF, accurate drug release can be realized in a tumor-specific microenvironment, the toxicity of normal cells can be remarkably reduced, the treatment effect is improved, and a wide clinical application prospect is shown.

The invention discloses a polypeptide-based PROTAC condensation body as well as a preparation method and application of the polypeptide-based PROTAC condensation body. The polypeptide-based PROTAC aggregate comprises an HER2 (human epidermal growth factor receptor) targeting module, an EGFR (epidermal growth factor receptor) targeting module, a VHL E3 ligase targeting module and a self-assembly module. The polypeptide-based PROTAC condensation body can dynamically enrich E3 ligase VHL and promote efficient ubiquitination degradation of HER2, EGFR and downstream signal channel protein of HER2 and EGFR, the degradation efficiency of HER2 and EGFR protein can reach 92%, the degradation efficiency of downstream signal channel protein such as SOS2 and RAS can reach 80%, and in addition, the polypeptide-based PROTAC condensation body has the advantages that the polypeptide-based PROTAC condensation body can be used as an efficient ubiquitination condensation body; the polypeptide-based PROTAC condensation body has the characteristics of tumor targeting and long-acting retention, and dose-dependent tumor specific accumulation and retention can be realized through in-situ self-assembly.

The invention provides a puncture sample detection platform based on a tumor protein targeting probe. According to the puncture sample detection platform, IR-780 is used for marking tumor specific protein in a puncture sample; the improved three-dimensional gel electrophoresis device is used for separating proteins in tissues; the gel processing platform is used for processing and analyzing the separation gel medium; and the automatic diagnosis platform is used for automatically judging benign and malignant conditions of the puncture sample according to the intensity and coherence of the fluorescence signal and circling the contour of the malignant sample. Compared with clinical pathological examination, the method has the advantages that benign and malignant puncture samples are judged by evaluating the protein content of various tumor receptors, and the problem of diagnosis difficulty caused by limited histological information is well solved. Meanwhile, the dependence on visual diagnosis of pathological analysis of the frozen section and experience of pathologists is reduced, and the accuracy and efficiency of pathological tissue diagnosis are effectively improved. The automatic diagnosis platform can eliminate a large number of benign samples and can reduce repeated work of pathologists.

The invention relates to an immune sensitization IRE treatment platform based on NK cell membrane coated manganese carbonate. A manganese carbonate composite nano material is formed by coating the surfaces of manganese carbonate nano particles with cell membranes. According to the invention, higher tumor specificity enrichment is realized, non-target tissue accumulation and systemic toxicity risks are reduced, collaborative integration of tumor targeted delivery, immune activation and IRE ablation is realized, and compared with single IRE, anti-tumor immune response is significantly enhanced.

The invention provides a compound for releasing a urine fluorescent biomarker under induction of mitochondrial DNA mutation as well as a preparation method and application of the compound, and belongs to the technical field of medicines. The compound disclosed by the invention is prepared by the following steps: complementarily pairing a hybrid nucleic acid nano-carrier containing single-stranded DNA (Deoxyribose Nucleic Acid), an annular fluorescent reporter molecule and a Cas12a / crRNA compound through bases of DNA or RNA, and then coating polyethyleneimine and hyaluronic acid. A CRISPR / Cas12a system is selected as a converter of tumor specific mitochondrial DNA mutation information and urine fluorescence signals, a nano delivery system which responds to mtDNA single base mutation and is used for tumor progress monitoring and early metastasis warning is designed and synthesized, and the nano delivery system has a good application prospect in tumor progress monitoring and early metastasis sensitive detection.

The invention belongs to the technical field of biological medicines, and particularly relates to a recombinant oncolytic herpesvirus and application thereof. In order to solve the problems of insufficient replication efficiency, limited immune activation and the like of the existing oncolytic herpesvirus, the invention provides a recombinant oncolytic herpesvirus which contains a coding neurotoxic factor regulated by a tumor specific promoter or a gene related to replication and a gene segment for coding an immunomodulatory factor. Experiments prove that the recombinant oncolytic herpesvirus prepared by the invention has multiple advantages of high replication efficiency, strong tumor targeting, remarkable treatment effect on various tumors, high safety and the like, provides a brand new drug development thought and treatment choice for the field of tumor immunotherapy, and has important clinical application value and market prospect.

The present invention relates to methods for predicting T cell epitopes. In particular, the present invention relates to methods for predicting whether a modification in a peptide or polypeptide, such as a tumor-associated neoantigen, is immunogenic. The methods of the present invention are particularly suitable for providing a vaccine specific to a patient's tumor and, therefore, are suitable for use in the context of personalized cancer vaccines.

Methods for detecting a tumor using a sample in which tumor DNA fragments are present only in a very low concentration, beyond the statistical limit of detection, where methods include: obtaining sequence data for tumor nucleic acid from a tumor from a subject and analyzing the sequence data to identify a plurality of tumor-specific variants that are in the tumor nucleic acid and that are not in non-tumor nucleic acid of the subject; selecting a marker variant that appears duplicated in tumor nucleic acid (compared to non-tumor nucleic acid) a greater number of times than other ones of the tumor variants; performing an assay to detect the marker variant in a sample from the subject; and reporting the presence of the tumor in the subject when the assay is positive for the marker variant in the sample.

Provided herein are activatable anti-human CTLA-4 antibodies comprising a heavy chain comprising a VH domain and a light chain comprising a masking moiety (MM), a cleavable moiety (CM), and a VL domain. Such activatable anti-human CTLA-4 antibodies have CTLA-4 binding activity in the tumor microenvironment, where the masking moiety is removed by proteolytic cleavage of the cleavable moiety by tumor-specific proteases, but exhibit greatly reduced binding to CTLA-4 outside the tumor. In this way, the activatable anti-human CTLA-4 antibodies of the present invention retain anti-tumor activity while reducing the side effects associated with anti-CTLA-4 activity outside the tumor.

The invention discloses a CT image whole-body multi-tumor segmentation method, which comprises the following steps: firstly, preprocessing collected CT images of multiple parts and multiple types of tumors, then inputting the preprocessed images into a pre-trained organ segmentation model, and obtaining segmentation results of different organs and local tumor images of different parts; thirdly, extracting and fusing features by utilizing global and local tumor segmentation models, and enhancing extraction of tumor specific features by taking an organ segmentation result as guide information and combining tumor text prompts generated by a large language model; and finally, carrying out step-by-step up-sampling through a decoder to obtain an accurate tumor segmentation image. According to the invention, global and local features are integrated, and an organ segmentation result is used as guidance to form a position attention module, so that the adaptability of the model to different organ tumors is enhanced; through a tumor text prompt driving mechanism of a large language model, specific hyper-parameters for each tumor are generated, and the accuracy and robustness of the model in a multi-part and multi-type tumor segmentation task are improved.

The invention relates to application of PWWP2B as a target spot in preparation of leukemia treatment drugs, and belongs to the technical field of biological medicines. In order to solve the problem that a traditional AML treatment target is lack of tumor specificity and is difficult to meet clinical requirements, the invention provides application of PWWP2B as a target in preparation of leukemia treatment drugs. The invention proves that PWWP2B is highly expressed in acute myelogenous leukemia cells, and the PWWP2B as a molecular marker can accurately distinguish acute myelogenous leukemia from normal healthy people or non-leukemia patients. In-vivo and in-vitro experiments prove that by knocking out PWWP2B, proliferation and clone formation of acute myelogenous leukemia cells can be remarkably inhibited, differentiation and apoptosis of the acute myelogenous leukemia cells are promoted, and activity of leukemia cells in a patient body is inhibited. The invention discloses the new application of the small molecule compound EZM0414 in treating acute myelogenous leukemia for the first time, and the synergistic interaction of the small molecule compound EZM0414 and a methylase inhibitor can be realized.

A system and method for generation and use of radiation outcome prediction (response & side effects) score for patients undergoing radiotherapy for various medical conditions wherein the score is a personalized score, provided by analyzing multiple parameters including the tumor specific, patient specific, gene specific and treatment planning specific parameter(s), during and post therapy.

The application relates to the field of biological preparations, and particularly discloses an immunochromatographic reagent for detecting malignant tumors in urine and application thereof, which is used for solving the problems of poor recognition of tumor specific epitopes, heavy background interference, spectrum overlap and high subjectivity of artificial judgment in the single staining and color development of acridine orange in the detection of urinary exfoliative cells of bladder cancer. The color development reagent comprises A reagent, B reagent, C reagent and D reagent. The A reagent is provided with an antibody complex for target antigens of bladder tumor cells in urine exfoliation and acridine orange. The B reagent comprises a fluorescently labeled secondary antibody composition corresponding to the A reagent and an enzyme-labeled secondary antibody-tyramide deposition amplification composition. In the application, AI imaging analysis is adopted to calibrate layered recognition labels and acridine orange staining negative and positive labels. Through multi-target immunochromatography, two sets of color separation amplification schemes and AI imaging analysis, the application improves the recognition ability of bladder tumor specific epitopes, the image quality and the image analysis accuracy in the detection of urinary exfoliative cells.

Provided herein are immortalized mesenchymal stem cells comprising a replicating recombinant retrovirus. Methods for treating a cell proliferative disorder using these immortalized mesenchymal stem cells are also provided.

The present invention provides compounds of Formula (I) which can be used as CCR8 inhibitors, which can be used as treatment or prevention of cancer using CCR8 inhibitors targeted tumor specific T regulatory cells.

This disclosure relates to a technique for identifying tumor-specific mutations through integrated analysis of next-generation sequencing data using machine learning models. In certain embodiments, a computer implementation method is provided, comprising: generating sequence reads from one or more samples collected from the same patient; generating variant calling files by analyzing the sequence reads corresponding to each of the one or more samples; generating a list of candidate somatic variants by comparing the variant calling files; generating a score for each of the candidate somatic variants in the list of candidate somatic variants using a classification machine learning model, wherein the score is generated based on a plurality of classifications generated by the classification machine learning model; determining the ctDNA status for the patient based on the score, wherein the ctDNA status is either positive or negative; and generating a report providing the ctDNA status for the patient.

The invention relates to a tumor hypoxia specific response BODIPY fluorescent probe as well as preparation and application thereof. The invention relates to a BODIPY fluorescent probe which is synthesized by utilizing tumor hypoxia to respond to azobenzene groups. The probe has no signal to normal oxygen cells, shows strong near-infrared fluorescence to hypoxia cancer cells, and can be used for visually detecting deep solid tumors. According to the present invention, the tumor specific response BODIPY fluorescent probe is adopted as the research object, the human liver cancer cells (HepG2) and the human non-small cell lung cancer cells (A549) are adopted as the tested cell strains, the fluorescence detection ability research under the normal oxygen and oxygen deficiency conditions is developed, and the foundation is established for the real-time accurate tumor detection. The fluorescent probe has the advantages of lower preparation cost, simpler synthesis method, easily available raw materials, less side reaction, high yield, easiness in purification, easiness in industrial production and the like.

The invention provides a targeted degradable protein and application thereof, and belongs to the technical field of biological medicine. The amino acid sequence of the targeted degradation protein is SEQ ID NO.1. When the targeted degradation protein is used for treating breast cancer, target protein degradation can be directly mediated, so that the effect of the target protein is weakened fundamentally, the targeted degradation protein only needs to be combined with the target protein with very strong affinity, specific epitopes do not need to be combined, the design difficulty is low, and the number of adaptive targets is large. Therefore, the targeted degradation protein provided by the invention takes the membrane molecule with high expression of tumor specificity as the effect protein, so that the dual effects of tumor targeting and mediated endocytosis are realized.

The present invention discloses a metal complex tailed with an immunologically active molecule, as well as its preparation method and application. The metal complex tailed with an immunologically active molecule exhibits significant anticancer activity. On the one hand, the metal complex exerts cytotoxicity against rapidly growing cancer cells through its active ingredient with anti-tumor immune efficacy. On the other hand, it can also induce immunogenic cell death, enabling the host immune system to attack tumor cells and induce a tumor-specific immune response. (The metal complex of the present invention has been shown to effectively induce immunogenic cell death in non-small cell lung cancer cells and successfully activate anti-tumor immunity in mice in vaccine experiments.) Therefore, the metal complex of the present invention has outstanding effects in anti-cancer, anti-inflammatory, inducing immunogenic cell death, and achieving anti-tumor immunity, and has broad application prospects.

The invention provides a multiple detection technology MMDEC for high-sensitivity detection of tumor methylated DNA from samples such as blood, belongs to the field of disease diagnosis markers, and more specifically relates to a method for detecting methylation of target DNA through the following steps: constructing oligonucleotide; the kit comprises a target specific multiple Rooptag primer capable of being complementarily combined with a plurality of tumor specific high-methylated CG island target DNAs (Deoxyribose Nucleic Acid) and a universal tag primer combined with the specific multiple Rooptag primer, wherein the target specific multiple Rooptag primer can be complementarily combined with a plurality of tumor specific high-methylated CG island target DNAs (Deoxyribose Nucleic Acid); the method comprises the following steps: performing exponential amplification on multiple methylation target DNA by using a specific multiple Rooptag primer as a primary primer to obtain a multiple amplification product; performing homogeneity amplification on the obtained multiplex amplification primer by using oligonucleotide (which can be complementarily combined with the linearly amplified target DNA) using a universal tag primer as a secondary primer; and detecting whether an amplification product exists or not through a probe. According to the method disclosed by the invention, MMDEC can be used for early screening and diagnosis of plasma / urine sample tumors, accords with clinical practice on the basis of research results, and has a good clinical application prospect.

The present invention belongs to the field of medicinal chemistry and specifically discloses a light-responsive ion pair composition and its anti-cancer application. The ion pair composition includes a cyclometallic gold (III) complex and a photosensitizer, wherein the photosensitizer includes eosin (EY) or rose bengal (RB), and the structural formula of the cyclometallic gold (III) complex is shown in formula (1). The composition modifies the structure of the known cyclometallic gold (III) complex skeleton by adding hydroxyl groups, morpholine rings and deuteration, thereby improving its water solubility, charge properties, stability and other aspects. It can be efficiently activated by green light or even red light and has anti-cancer applications. The present invention achieves efficient activation of the cyclometallic gold (III) complex by combining the cyclometallic gold (III) complex with eosin (EY) or rose bengal (RB), and can extend the excitation wavelength to the red light range; and based on the ion pair properties and the characteristics of the tumor microenvironment, tumor-specific treatment can be achieved more accurately on the basis of light irradiation.

The invention relates to the technical field of magnetic particle imaging, in particular to a core-shell nanoprobe and a preparation method and application thereof.The core-shell nanoprobe comprises a magnetic core and a nanoshell which is located outside the magnetic core and has a magnetic shielding response function, and the structure of the nanoshell collapses under the tumor microenvironment condition; the saturation magnetization of the magnetic core is greater than or equal to 50 emu / g, and the coercive force is less than or equal to 5 Oe; the saturation magnetization of the nano shell is less than 50 emu / g, and the coercive force is more than 5 Oe. According to the core-shell nanoprobe, through a unique magnetic core-shell structure design and tumor microenvironment response characteristics, a magnetic shielding layer is formed by using a low-signal nano shell with a response magnetic shielding function, and background signal interference is inhibited. In a tumor microenvironment, the shell structure of the core-shell nanoprobe collapses, the magnetic core is exposed, and a high magnetic signal is released and generated, so that the imaging signal-to-noise ratio is remarkably improved. According to the invention, the bottleneck that the traditional MPI probe is lighted in the whole course can be broken through, the tumor specificity is lighted and positioned, and the problems that the external background of the tumor is high, the contrast ratio is poor, and tiny focuses are difficult to detect are solved.

Therapeutic polypeptides, compositions thereof and methods of use thereof for activating NK cells and treating tumors are provided. The therapeutic polypeptides can include a first domain for binding NKG2D and a second domain for binding a tumor target.

The application discloses a micro serum tumor whole-process screening detection method based on nucleic acid aptamer group comparison, and comprises the following steps: firstly, 24+1 tumor and non-tumor specific nucleic acid aptamer groups are screened by using bidirectional thermal cycle subtraction SELEX technology; data of the specific nucleic acid aptamer groups are used to create a standard database; the specific nucleic acid aptamer groups are mixed in equal proportions to develop 24+1 tumor and non-tumor specific nucleic acid aptamer detection reagents; in the detection process, the detected sample forms a magnetic bead-sample serum protein complex, and then is combined with the aptamer detection reagent; a magnetic bead-serum protein-sample specific nucleic acid aptamer complex is formed, and sample specific nucleic acid aptamer is separated and obtained; and the sample specific nucleic acid aptamer is compared and analyzed with the standard database, so that the sample detection technology method is realized. The method has the advantages of small sample amount, automatic process completion, high throughput, wide tumor screening range and the like, and meets the requirements of high-throughput tumor screening.

The application provides a non-contact pain monitoring mattress and system based on multi-modal physiological signal fusion, the mattress body comprises, from bottom to top, a bottom support layer, a signal shielding layer, a sensing core layer and a breathable skin-friendly layer, the system comprises the non-contact pain monitoring mattress, a low-noise charge amplifier, a fiber demodulator, an edge computing gateway and a cloud analysis center, the data after signal conditioning is transmitted to the edge computing gateway and uploaded to the cloud analysis center, and the cloud analysis center performs quantitative scoring through a tumor-specific pain model.The application has the advantages that no electrode or wearable device needs to be pasted, the skin irritation and psychological burden of traditional monitoring are completely eliminated, the patient compliance is improved, the limitation of subjective evaluation is broken through, an objective pain evaluation method is provided for patients in the late stage / aphasia, multi-modal signal fusion monitoring is used to effectively distinguish pain from ordinary emotional fluctuations, the degree of pain is fed back in real time, the doctor is assisted in dynamically adjusting the dose of analgesic drugs, and the risk of drug overdose and deficiency is reduced.

The invention discloses a tumor specific signal analysis device and equipment for uncertain pulmonary nodules and a storage medium, and relates to the technical field of electrical digital data processing.The device constructs a LungTCR database containing lung cancer tissue enrichment type and blood enrichment type CDR3 sequences through TCR beta chain sequencing and IMGT database comparison, and the LungTCR database is used for analyzing the lung cancer tissue enrichment type and blood enrichment type CDR3 sequences. A basis is provided for tumor specific signal recognition; a Needleman-Wunsch algorithm and an editing distance threshold value are adopted for screening, so that high-precision sequence matching is realized; through quantification of lung cancer tissue scores, blood scores and mutation specificity scores, a TCR feature group with biological significance is formed; and finally, the TCRnodseek plus model trained by clinical and image features is combined, a reliable malignant probability prediction value can be output, the model AUC can reach 0.90 or above, and the model is obviously superior to traditional imaging diagnosis and tumor markers.